Literature DB >> 8554169

The urokinase plasminogen activator (u-PA) and its inhibitor (PAI-1) in embryo-fetal bone formation in the human: an immunohistochemical study.

C Häckel1, K Radig, I Röse, A Roessner.   

Abstract

The role of urokinase plasminogen activator and plasminogen activator inhibitor-1 in human embryo-fetal bone formation between the 9th and the 20th week of gestation has been studied immunohistochemically. While mature osteocytes of the secondary spongiosa and resting chondrocytes of the bone epiphyses were negative for both antigens in each developmental stage, metabolically active parts of the osseocartilaginous system showed a strong immunoreactivity. Until the end of the 10th week of gestation urokinase plasminogen activator and plasminogen activator inhibitor-1 could not be demonstrated in the shaft of the preexisting cartilaginous models of bones, which correlates with the morphological developmental stage of the embryos. Later, osteoblasts and chondrocytes in the areas of enchondral ossification, and the perivascular chondrocytes of the epiphyseal secondary ossification centres, showed similarly high concentrations of urokinase plasminogen activator and plasminogen activator inhibitor-1. Moreover, the individual ossification stages of the different bones in embryo-fetal development could be demonstrated immunohistochemically. While humeri and femora showed diaphyseal immunoreactivities at an early stage, positive reactions in the phalanges were found only much later. Thus, the enzymes of the fibrinolytic system studied are clearly involved in the desmal and enchondral ossification process in the osseocartilaginous compartment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554169     DOI: 10.1007/bf00710105

Source DB:  PubMed          Journal:  Anat Embryol (Berl)        ISSN: 0340-2061


  17 in total

1.  Monoclonal antibodies against human high molecular weight urinary urokinase: application for affinity purification of urinary prourokinase.

Authors:  J Wojta; J C Kirchheimer; L Turcu; G Christ; B R Binder
Journal:  Thromb Haemost       Date:  1986-06-30       Impact factor: 5.249

2.  Effects of interleukin-1, tumor necrosis factor -beta, and forskolin on tissue plasminogen activator activity in human osteoblastic osteosarcoma cells.

Authors:  A C Kohl; D N Tatakis; C Hansen; R Dziak
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

3.  Types I and IV collagenolytic and plasminogen activator activities in preovulatory ovarian follicles.

Authors:  A Palotie; T Salo; K K Vihko; L Peltonen; H Rajaniemi
Journal:  J Cell Biochem       Date:  1987-06       Impact factor: 4.429

4.  Transforming growth factor-beta modulates the expression of osteoblast and chondroblast phenotypes in vitro.

Authors:  D M Rosen; S A Stempien; A Y Thompson; S M Seyedin
Journal:  J Cell Physiol       Date:  1988-03       Impact factor: 6.384

5.  Rapid isolation of high molecular weight urokinase from native human urine.

Authors:  K Huber; J Kirchheimer; B R Binder
Journal:  Thromb Haemost       Date:  1982-06-28       Impact factor: 5.249

6.  Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists.

Authors:  E H Allan; J A Hamilton; R L Medcalf; M Kubota; T J Martin
Journal:  Biochim Biophys Acta       Date:  1986-09-19

7.  Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.

Authors:  G Nicoloso; J Hauert; E K Kruithof; G Van Melle; F Bachmann
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

8.  Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.

Authors:  O F Wagner; M Vetterlein; B R Binder
Journal:  J Biol Chem       Date:  1986-11-05       Impact factor: 5.157

9.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.

Authors:  G I Goldberg; A Strongin; I E Collier; L T Genrich; B L Marmer
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

10.  Meiotic maturation of mouse oocytes triggers the translation and polyadenylation of dormant tissue-type plasminogen activator mRNA.

Authors:  J Huarte; D Belin; A Vassalli; S Strickland; J D Vassalli
Journal:  Genes Dev       Date:  1987-12       Impact factor: 11.361

View more
  2 in total

1.  Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation.

Authors:  Nathalie Ortega; Ke Wang; Napoleone Ferrara; Zena Werb; Thiennu H Vu
Journal:  Dis Model Mech       Date:  2010-02-08       Impact factor: 5.758

2.  Cyclic tensile strain enhances osteogenesis and angiogenesis in mesenchymal stem cells from osteoporotic donors.

Authors:  Adisri Charoenpanich; Michelle E Wall; Charles J Tucker; Danica M K Andrews; David S Lalush; Douglas R Dirschl; Elizabeth G Loboa
Journal:  Tissue Eng Part A       Date:  2013-09-19       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.